Mansi Shah Highlights Promising CNS Activity of Bispecific Antibodies
Mansi Shah, Clinical Associate Professor at Rutgers Cancer Institute, shared a post on X:
“Our multicenter series shows bispecific antibodies may offer meaningful CNS activity with manageable safety. Led by fellow Alex N!”
Hira Mian, Multiple Myeloma Lead of Juravinski Cancer Centre at Hamilton Health Sciences, shared this post, adding:
“Thank you for sharing this study, this is really helpful for those rare scenarios that we are somehow now increasingly seeing. Appreciate this.
Absolutely! It was inspired by several initial payor denials I received when trying to use bsabs for patients with cns involvement of multiple myeloma citing lack of data. Now we have it!”
Title: Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort
Authors: Alexandra Noveihed, Samer Al Hadidi, Meera Mohan, Mansi Shah
More posts featuring Bispecific Antibodies on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023